

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/714689
				Filing Date	2003-11-17
				First Named Inventor	LOU; Sheng C.
				Art Unit	1648
				Examiner Name	PARKIN, Jeffrey S.
Sheet	1	of	6	Attorney Docket No: 6755USD1	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	001	US4945042	07-31-1990	GEIGER, Thomas et al.		
	002	US5156949	10-20-1992	LUCIW, Paul A. et al.		
	003	US5627026	03-06-1997	O'CONNOER, Thomas et al.		
	004	US20030049604	03-13-2003	CHARNEAU, Pierre et al.		
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
	005	DE19727943A1	09-24-1998	BOEHRINGER MANNHEIM GMBH, 68305 MANNHEIM, DE.		<input checked="" type="checkbox"/>
	006	DE4236189A1	04-28-1994	BOEHRINGER MANNHEIM GMBH.		<input type="checkbox"/>
	007	EP186799A1	07-09-1986	BEHRINGWERKE AKTIENGESELLSCHAFT.		<input type="checkbox"/>
	008	EP246829B1	11-25-1987	VIRAL TECHNOLOGIES, INC.		<input checked="" type="checkbox"/>
	009	EP265851A2	05-04-1988	BEHRINGWERKE AKTIENGESELLSCHAFT.		<input checked="" type="checkbox"/>
	010	EP280211A2	08-31-1988	BOEHRINGER MANNHEIM GMBH.		<input checked="" type="checkbox"/>
	011	EP345375A1	12-13-1989	INNOGENETICS N.V.		<input type="checkbox"/>
	012	EP345461B1	09-28-1994	ABBOTT LABORATORIES.		<input checked="" type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/714689
				Filing Date	2003-11-17
				First Named Inventor	LOU; Sheng C.
				Art Unit	1648
				Examiner Name	PARKIN, Jeffrey S.
Sheet	2	of	6	Attorney Docket No: 6755USD1	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ² (if known)				
	013	EP351248B1	01-17-1990	IDEXX LABORATORIES		<input type="checkbox"/>
	014	EP386713B1	09-18-1990	ABBOTT LABORATORIES.		<input checked="" type="checkbox"/>
	015	EP595211A1	05-04-1994	BOEHRINGER MANNHEIM GMBH.		<input checked="" type="checkbox"/>
	016	WO9429725A1	12-22-1994	ABBOTT LABORATORIES. et al.		<input type="checkbox"/>
	017	WO9523973A3	09-08-1995	ABBOTT LABORATORIES.		<input type="checkbox"/>
	018	WO9603423A1	02-08-1996	BOEHRINGER MANNHEIM GMBH. et al.		<input type="checkbox"/>
	019	WO9603651A1	02-08-1996	BOEHRINGER MANNHEIM GMBH. et al.		<input type="checkbox"/>
	020	WO9603652A1	02-08-1996	BOEHRINGER MANNHEIM GMBH. et al.		<input type="checkbox"/>
	021	WO9612809A2	05-02-1996	INSTITUT PASTEUR. et al.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
	022	"ACADEMIC PRESS DICTIONARY OF SCIENCE AND TECHNOLOGY", PP.1808.	<input type="checkbox"/>
	023	APETREI et al., "Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions", AIDS, 1996, 10, F57-F60.	<input type="checkbox"/>
	024	Budapest treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure, Deposits of DSM ACC2299, DSM ACC2300, DSM ACC2301, and DSM ACC2310, all dated March 11, 1997.	<input type="checkbox"/>
	025	CLAVEL, Francois, "HIV-2, the West African AIDS Virus," AIDS, 1987, pp. 135-140, Vol. 1.	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		<i>Complete if Known</i>		
		Application Number	10/714689	
		Filing Date	2003-11-17	
		First Named Inventor	LOU; Sheng C.	
		Art Unit	1648	
		Examiner Name	PARKIN, Jeffrey S.	
Sheet	3	of	6	Attorney Docket No: 6755USD1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
	026	CONSTANTINE et al., "Serologic tests for the retroviruses: approaching a decade of evolution", AIDS, 1993, 7, 1-13.	<input type="checkbox"/>
	027	COUROUCE et al., "Effectiveness of assays for antibodies to HIV and p24 antigen to detect very recent HIV infections in blood donors. The Retrovirus Study Group of the French Society of Blood Transfusion", AIDS, 6 (12), 1992, pp. 1548-1550.	<input type="checkbox"/>
	028	FILICE et al., "Sensitivity and specificity of anti-HIV ELISA employing recombinant and synthetic viral antigenic peptides" (p24, p66. gp120) (gp41) ", MICROBIOLOGICA, 14, pp. 185-194, 1991.	<input type="checkbox"/>
	029	GALLARDA et al., "Early Detection of Antibody to Human Immunodeficiency Virus Type 1 by Using an Antigen Conjugate Immunoassay Correlates with the Presence of Immunoglobulin M Antibody", JOURNAL OF CLINICAL MICROBIOLOGY, 1992, p. 2379-2384 Vol. 30, No. 9.	<input type="checkbox"/>
	030	GITTI et al., "Structure of the Amino-Terminal Core Domain of the HIV-1 Capsid Protein", SCIENCE, 273, 1996, p. 231-235.	<input type="checkbox"/>
	031	GLASER et al., "Binding kinetics of an antibody against HIV p24 core protein measured with real-time biomolecular interaction analysis suggest a slow conformational change in antigen p24", Journal of Immunological Methods, 189, 1996, pp. 1-14.	<input type="checkbox"/>
	032	HASHIDA et al., "Earlier Diagnosis of HIV-I Infection by Simultaneous Detection of p24 Antigen and Antibody IgGs to pi7 and Reverse Transcriptase in Serum With Enzyme Immunoassay," Journal of Clinical Laboratory Analysis, 1996, pp. 213-219, Vol. 10, Wiley-Liss, Inc.	<input type="checkbox"/>
	033	HASHIDA et al., "Immune Complex Transfer Enzyme Immunoassay That Is More Sensitive and Specific than Western Blotting for Detection of Antibody Immunoglobulin G to Human Immunodeficiency Virus Type 1 in Serum with Recombinant pol and gag Proteins as Antigens," Clinical And Diagnostic Laboratory Immunology, 1995, pp. 535-541, Vol. 2 (5).	<input type="checkbox"/>
	034	HASHIDA et al., "Shortening of the window period in diagnosis of HIV-I infection by simultaneous detection of p24 antigen and antibody IgG to pi7 and reverse transcriptase in serum with ultrasensitive enzyme immunoassay," Journal of Virological Methods, 1996, pp. 43-53, Vol. 62.	<input type="checkbox"/>
	035	HINKULA et al., "EPI TOPE MAPPING OF THE HIV-1 gag REGION WITH MONOCLONAL ANTIBODIES", Molecular Immunology, Vol. 27, No. 5, pp. 395-403,	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/714689
				Filing Date	2003-11-17
				First Named Inventor	LOU; Sheng C.
				Art Unit	1648
				Examiner Name	PARKIN, Jeffrey S.
Sheet	4	of	6	Attorney Docket No: 6755USD1	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2	
		1990.		
	036	International Search Report for application no. PCT/US2001/43179, Mailed on 05/12/2002, 4 pages.	<input type="checkbox"/>	
	037	JANVIER et al., "Linear B-Cell Epitopes of the Major Core Protein of Human Immunodeficiency Virus Types 1 and 2", J. Virol., 64 (9), 4258-4263, 1990.	<input type="checkbox"/>	
	038	JANVIER et al., "Linear B-Cell Epitopes of the Major Core Protein of Human Immunodeficiency Virus Types 1 and 2", Author's Correction, J. Virol., 66(1), 1990, 613.	<input type="checkbox"/>	
	039	KUSK et al., "Mapping of Linear B-Cell Epitopes on the Major Core Protein p24 of Human Immunodeficiency Virus Type 1 (HIV-1), AIDS RESEARCH AND HUMAN RETROVIRUSES, 8 (10), 1992, 1789-1794.	<input type="checkbox"/>	
	040	MULLER et al., "Co-expression of the Subunits of the Heterodimer of HIV-1 Reverse Transcriptase in Escherichia coli", JOURNAL OF BIOLOGICAL CHEMISTRY, 264 (24), 13975-13978, 1989.	<input type="checkbox"/>	
	041	NG, Valerie et al., "Reliable Confirmation of Antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) with an Enzyme-Linked Immunoassay Using Recombinant Antigens Derived from the HIV-1 gag, pol, and env Genes", JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (5), p. 977-982.	<input type="checkbox"/>	
	042	NIEDRIG et al., "Monoclonal Antibodies Directed against Human Immunodeficiency Virus (HIV) gag Proteins with Specificity for Conserved Epitopes in HIV-1, HIV-2 and Human Immunodeficiency Virus", J. Gen. Virol, 1988, 69, 2109-2114.	<input type="checkbox"/>	
	043	POLLET et al., "Confirmation and Differentiation of Antibodies to Human Immunodeficiency Virus 1 and 2 with a Strip-Based Assay Including Recombinant Antigens and Synthetic Peptides," Clinical Chemistry, 1991, pp. 1700-1707, Vol. 37.	<input type="checkbox"/>	
	044	RAPPORT de stage, "Caracterisation des epitopes de la protein p24 du virus VIH-1 par le systeme NOVATOPE", 1998.	<input type="checkbox"/>	
	045	ROBERT-HEBMANN et al., "CLONAL ANALYSIS OF MURINE B CELL RESPONSE TO THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV1)-gag 1, 17 AND p25 ANTIGENS", Molecular Immunology, Vol. 29, No 6, 1991, 729-738.	<input type="checkbox"/>	
	046	SAITOH et al., "Overproduction of Human Immunodeficiency Virus Type I Reverse Transcriptase in Escherichia coli and Purification of the Enzyme", Microbiol. Immunol., Vol. 34 (6), 509-521, 1990.	<input type="checkbox"/>	

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/714689
				Filing Date	2003-11-17
				First Named Inventor	LOU; Sheng C.
				Art Unit	1648
				Examiner Name	PARKIN, Jeffrey S.
Sheet	5	of	6	Attorney Docket No: 6755USD1	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2	
	047	SCHOCHETMAN et al., "AIDS Testing," Springer Verlag, New York, Berlin, Heidelberg, 1994, 411.	<input type="checkbox"/>	
	048	SHARP et al., "Origins and diversity of human immunodeficiency viruses", AIDS, 1994, 8 (suppl 1), 27-42.	<input type="checkbox"/>	
	049	SIMON et al., "Reliability of western blotting for the confirmation of HIV-1 seroconversion", Lancet, 1992, 340 (8834-8835), 1541-1542.	<input type="checkbox"/>	
	050	TIJSSEN P. "Laboratory techniques in biochemistry and molecular biology", Table of Contents, 1985, Volume 15 (Burdon and van Knippenberg, Eds.).	<input type="checkbox"/>	
	051	USHIO et al., "Cloning of the cDNA for Expression in Escherichia Activities of the Protein Human IFN-gamma-Inducing Factor, Expression in Escherichia coli, and Studies on the Biologic Activities of the Protein", The Journal of Immunology, 156, 1996, P. 4274-4279.	<input type="checkbox"/>	
	052	WEBER et al., "Evaluation of the reliability of 6 current anti-HIV-1/ HIV-2 enzyme immunoassays", Journal of Virological Methods, 55, 1995, pp. 97-104.	<input type="checkbox"/>	
	053	WEBER et al., "The use of recombinant antigens in ELISA procedures for the quantification of intrathecally produced HIV-1-specific antibodies," Journal of Immunological Methods, 1991, pp. 133-137, Vol. 136.	<input type="checkbox"/>	
	054	WEBER et al., "Quantitative Detection of Human Immunodeficiency Virus (HIV) Antigen by the Enzymun-Test: Comparison with Alternative Assays and Nucleic Acid Sequence-Based Amplification of HIV Type 1 RNA," Journal of Clinical Microbiology, 1986, 34, 6, pp. 1440-1447.	<input type="checkbox"/>	
	055	Bohringer Mannheim Immunodiagnostics, ENZYMUN-TEST® HIV combi, Catalog No. 1877631, Product insert sheet release 698-1936107001 05 02, 2004	<input type="checkbox"/>	
	056	ZAAIJER et al., "Early detection of antibodies to HIV-1 by third-generation assays", Lancet, 340, 1992, 770-772.	<input type="checkbox"/>	

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.